MX2021012857A - Composiciones y metodos utilizables para el tratamiento del ojo seco. - Google Patents
Composiciones y metodos utilizables para el tratamiento del ojo seco.Info
- Publication number
- MX2021012857A MX2021012857A MX2021012857A MX2021012857A MX2021012857A MX 2021012857 A MX2021012857 A MX 2021012857A MX 2021012857 A MX2021012857 A MX 2021012857A MX 2021012857 A MX2021012857 A MX 2021012857A MX 2021012857 A MX2021012857 A MX 2021012857A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- compositions
- dry eye
- treatment
- integrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836858P | 2019-04-22 | 2019-04-22 | |
| PCT/US2020/029168 WO2020219475A1 (en) | 2019-04-22 | 2020-04-21 | Compositions and methods useable for treatment of dry eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012857A true MX2021012857A (es) | 2021-12-10 |
Family
ID=72941233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012857A MX2021012857A (es) | 2019-04-22 | 2020-04-21 | Composiciones y metodos utilizables para el tratamiento del ojo seco. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200345805A1 (https=) |
| EP (1) | EP3958915A4 (https=) |
| JP (1) | JP2022529823A (https=) |
| KR (1) | KR20220003548A (https=) |
| CN (1) | CN114040783A (https=) |
| CA (1) | CA3134362A1 (https=) |
| IL (1) | IL287441A (https=) |
| MX (1) | MX2021012857A (https=) |
| WO (1) | WO2020219475A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346362B (es) * | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
| US12454549B2 (en) | 2017-06-19 | 2025-10-28 | Jenius Pharma, Llc | Treatments for diseases and disorders that involve oxidative stress |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3128203B2 (ja) * | 1997-02-10 | 2001-01-29 | 一男 坪田 | 分泌腺細胞とリンパ球との接着阻害剤 |
| JP2000336030A (ja) * | 1999-03-24 | 2000-12-05 | Taisho Pharmaceut Co Ltd | 点眼液 |
| US20070104798A1 (en) * | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| JP4255656B2 (ja) * | 2001-09-17 | 2009-04-15 | 株式会社メニコン | 眼科用液剤及びコンタクトレンズ用液剤 |
| US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| DK2444079T3 (en) * | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| US10842669B2 (en) * | 2008-11-13 | 2020-11-24 | Gholam A. Peyman | Ophthalmic drug delivery method |
| ITRM20090102U1 (it) * | 2009-06-15 | 2010-12-16 | Alfa Intes Ind Terapeutica Splendore S R L | Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione. |
| MX346362B (es) * | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
| WO2011106697A1 (en) * | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| CA2849192C (en) * | 2011-10-12 | 2019-09-24 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
| TWI700085B (zh) * | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| US11433260B2 (en) * | 2015-12-21 | 2022-09-06 | Gholam A. Peyman | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy |
| PT3266446T (pt) * | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
| EP4389216A3 (en) * | 2017-06-19 | 2024-11-06 | Allegro Pharmaceuticals, LLC | Peptide compositions and therapeutic uses |
-
2020
- 2020-04-21 EP EP20794179.0A patent/EP3958915A4/en active Pending
- 2020-04-21 US US16/854,818 patent/US20200345805A1/en not_active Abandoned
- 2020-04-21 MX MX2021012857A patent/MX2021012857A/es unknown
- 2020-04-21 WO PCT/US2020/029168 patent/WO2020219475A1/en not_active Ceased
- 2020-04-21 KR KR1020217037228A patent/KR20220003548A/ko active Pending
- 2020-04-21 CN CN202080029842.3A patent/CN114040783A/zh active Pending
- 2020-04-21 CA CA3134362A patent/CA3134362A1/en active Pending
- 2020-04-21 JP JP2021562906A patent/JP2022529823A/ja active Pending
-
2021
- 2021-10-20 IL IL287441A patent/IL287441A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3958915A4 (en) | 2023-01-11 |
| IL287441A (en) | 2021-12-01 |
| CA3134362A1 (en) | 2020-10-29 |
| CN114040783A (zh) | 2022-02-11 |
| EP3958915A1 (en) | 2022-03-02 |
| US20200345805A1 (en) | 2020-11-05 |
| WO2020219475A1 (en) | 2020-10-29 |
| JP2022529823A (ja) | 2022-06-24 |
| KR20220003548A (ko) | 2022-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010502A (es) | Agentes farmacológicos para el tratamiento de enfermedades oculares. | |
| EP4349360A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| Vegger et al. | Additive effect of PTH (1–34) and zoledronate in the prevention of disuse osteopenia in rats | |
| MX2021012857A (es) | Composiciones y metodos utilizables para el tratamiento del ojo seco. | |
| MX2023001287A (es) | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. | |
| RU2020121540A (ru) | Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта | |
| JP2018500390A5 (https=) | ||
| HRP20211824T1 (hr) | Modulatori aktivnosti komplementa | |
| BR0015407A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para estimular a liberação de hormÈnio do crescimento da glândula pituitária de um mamìfero e para aumentar a taxa e o grau de crescimento, a produção de leite e de lã ou para o tratamento de dores, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| TW201620544A (zh) | 用於維持填充劑作用之組合物 | |
| CA2709027A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| Slautin et al. | Fucoxanthin enhances the antifibrotic potential of placenta-derived mesenchymal stem cells in a CCl4-induced mouse model of liver | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| RU2017126212A (ru) | Композиция | |
| ZA202101688B (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| MX2022004571A (es) | Alquilésteres de alfa-metil-dl-tirosina para uso en el tratamiento de cáncer. | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| MX2018011121A (es) | Prevención de la adherencia de tejido biológico. | |
| WO2019017677A3 (ko) | 시트랄을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
| JP2019507193A (ja) | 細菌のバイオフィルム形成を阻止又は妨害することによって眼障害を治療する方法 | |
| de Queiroz et al. | Calcitonin-gene related peptide is a potent inducer of oedema in rat orofacial tissue | |
| MX2021015796A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| WO2019017676A3 (ko) | 에틸바닐린을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor |